重庆医学2011，Vol.40Issue(26)：2611-2614,后插1,5.DOI:10.3969/j.issn.1671-8348.2011.26.005
TP、TC与NP方案治疗晚期非小细胞肺癌的系统评价
A systematic review in paclitaxel plus platinum versus vinorelbine plus cisplatin for advanced non small cell lungcancer
方向 1胡世莲 1沈干 2吴蕾 2孙玉蓓 3徐维平2
作者信息
- 1. 安徽医科大学附属省立医院老年医学科,合肥,230001
- 2. 安徽省循证医学中心,合肥,230001
- 3. 安徽省立医院肿瘤科,合肥,230001
- 折叠
摘要
Abstract
Objective To compare and evaluate the clinical efficacy and safety of paclitaxel plus platinum (TP and TC) versus vinorelbine plus cisplatin (NP) for patients with advanced non- small cell lung cancer.Methods Up to April 20l0,the computer search was done on Cochrane Library, Pubmed ,CBM , CNKI and Wanfang database , etc.to collect randomized controlled trials which involved comparison of paclitaxel plus platinum versus vinorelbine plus cisplatin for patients with advanced non-small cell lung cancer.Two reviewers evaluated the quality of included trials independently.The Cochrane Collaboration's software was used for metaanalyses.Results Nineteen studies involving 2593 patients were included.Metaanalysis demonstrated that the patients used TP and TC regimens had an equal medieval survival time,overall response rate and one-year survival rate in comparison with NP regimens.The toxicity analyses indicated that NP regimen led to more frequent grade 3 or 4 of leucopenia,neutropenia,anemia and nausea/vomiting, while TP and TC chemotherapy inclined to developing more grade 3 or 4 thrombocytopenia.Conclusion When the efficacy were similar between the vinorelbine plus cisplatin and paclitaxel plus platinum regimens, the choice of paclitaxel plus platinum or vinorelbine plus cisplatin depends on the toxicity of the drugs and patients' tolerance.关键词
癌,非小细胞肺/抗肿瘤联合化疗方案/长春瑞滨/紫杉醇/系统评价Key words
carcinoma , non- small cell lung / antineoplastic combined chemotherapy protocols / vinorelbine / paclitaxel / svstematic review引用本文复制引用
方向,胡世莲,沈干,吴蕾,孙玉蓓,徐维平..TP、TC与NP方案治疗晚期非小细胞肺癌的系统评价[J].重庆医学,2011,40(26):2611-2614,后插1,5.
